Navigation Links
Shanghai CRO Service Alliance Adds Clinical Development Capabilities

SHANGHAI, China, April 30 /Xinhua-PRNewswire/ -- Today, Tigermed Consulting Ltd. joins Sundia Meditech, HD BioSciences, and NovaSecta in their CRO Service Alliance CROSA that provides R&D solutions for pharmaceutical and biotech companies. Tigermed's expertise in clinical development complements the existing drug discovery and pharmaceutical development capabilities of the alliance.

Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO Service Alliance in May 2007 in order to quickly and successfully integrate their chemistry and biology expertise for the increased demands from their clients world-wide. Sundia and United merged into one company in the following months. NovaSecta joined the alliance in February 2008 to further integrate the alliance's work with European pharmaceutical and biotech companies.

Tigermed has a strong track record of providing clinical development services, data management and statistical support to multinational and smaller to medium sized pharmaceutical and biotech companies in US, Europe and Asia. Tigermed is also the clear leader in performing clinical trials in China on innovative New Chemical Entities (NCEs), which makes it an excellent potential partner for the pharmaceutical and biotech companies that Sundia, HD BioSciences and NovaSecta work with.

Through the addition of Tigermed to the alliance, clients can now benefit from a seamlessly integrated full R&D service covering discovery, non-clinical and clinical development.

About Sundia Meditech ( )

Sundia MediTech was founded in Shanghai in 2004 by veterans of the US pharmaceutical industry, and is now a leading CRO company in China. The founding team has talent and track record in organic synthesis, medicinal chemistry, drug design and discovery, process chemistry, cGMP API production, in vitro/vivo PK research, formulation development, analytical and bio- analytical areas. Sundia has successfully provided services in custom synthesis, library production, lead optimization (PD and PK), scale up, pre- clinical studies, cGMP API production and pharmaceutical development.

About HD BioSciences ( )

HD BioSciences, based in Shanghai, is one of the leading biology CRO companies in China. The company is known for its expertise in assay development, high-throughput screening (HTS), hit-to-lead solutions, high- throughput compound profiling, and natural compound-based lead identification. The company's proprietary assays and screening platforms give it a competitive edge in drug lead discovery services and in providing value to its partners and clients from pharmaceutical and biotech companies world-wide.

About NovaSecta ( )

NovaSecta is a specialist R&D service provider for smaller to mid-sized pharmaceutical and biotech companies ('MidPharmas'). Since its founding in early 2003, NovaSecta has built a unique network of relationships with MidPharmas in Europe and a deep understanding of how these companies manage and develop their R&D capabilities. NovaSecta's current business is originating and managing collaborations for MidPharmas; to date these have included a multi-company R&D program, product/project licensing and acquisitions, and scientific R&D collaborations.

About Tigermed ( )

Tigermed Consulting Ltd., based in Shanghai, is a leading CRO that specializes in pharmaceutical research and development. It offers a broad range of services including all phases of clinical studies, registration (for chemical and biological drugs, medical devices, etc.), new drug development and technology transfer, data management, GCP training, and market research. Since its founding in 2002, Tigermed has established long-term relationships with many clients in registration and clinical research.

SOURCE Sundia MediTech Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
2. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
3. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
4. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
5. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
6. The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring Last Lecturer Dr. Randy Pausch
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. United BioSource Acquires Leading Publication Planning Software and Services Company
9. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
10. EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Post Your Comments:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):